

# NATIONAL QUALITY FORUM

## Renal EM Submitted Measures

Measure ID/ Title	Measure Description	Measure Steward	Topic Area
<b>#1662</b> <b>Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy</b>	Percentage of patients aged 18 years and older with a diagnosis of CKD (not receiving RRT) and albuminuria (overt) who were prescribed ACE inhibitor or ARB therapy within a 12-month period	American Medical Association-Physician Consortium for Performance Improvement	ACE/ARB (CKD)
<b># 0252</b> <b>Assessment of Iron Stores</b>	Percentage of all adult (>=18 years old) hemodialysis or peritoneal dialysis patients prescribed an ESA at any time during the study period or who have a Hb <11.0 g/dL in at least one month of the study period for whom serum ferritin concentration AND either percent transferrin saturation or reticulocyte Hb content (CHR) are measured at least once in a three-month period for in-center hemodialysis patients, and at least twice during a six-month period for peritoneal dialysis patients and home hemodialysis patients.	Centers for Medicare and Medicaid Services	Anemia
<b># 1660</b> <b>ESRD Patients Receiving Dialysis: Hemoglobin Level &lt;10g/dL</b>	Percentage of calendar months within a 12-month period during which patients aged 18 years and older with a diagnosis of ESRD who are receiving hemodialysis or peritoneal dialysis have an average Hgb <10g/dL	American Medical Association-Physician Consortium for Performance Improvement	Anemia
<b># 1666</b> <b>Patients on Erythropoiesis Stimulating Agent (ESA)--Hgb Level &gt; or = 12g/dL</b>	Percentage of calendar months within a 12-month period during which patients aged 18 years and older with a diagnosis of advanced CKD (stage 4 or 5, not receiving RRT) or ESRD (who are on hemodialysis or peritoneal dialysis) are receiving ESA therapy and have an average Hgb Level > or = 12 g/dL	American Medical Association-Physician Consortium for Performance Improvement	Anemia
<b># 1667</b> <b>(Pediatric) ESRD Patients Receiving Dialysis: Hemoglobin Level &lt; 10g/dL</b>	Percentage of calendar months within a 12-month period during which patients aged 17 years and younger with a diagnosis of ESRD receiving hemodialysis or peritoneal dialysis have an average Hgb <10 g/dL	American Medical Association-Physician Consortium for Performance Improvement	Anemia (Pediatric)
<b># 1633</b> <b>Blood Pressure Management</b>	Percentage of patient visits for those patients aged 18 years and older with a diagnosis of CKD (stage 3, 4 or 5, not receiving RRT) and albuminuria with a blood pressure <130/80 mmHg OR >= 130/80 mmHg with a documented plan of care	American Medical Association-Physician Consortium for Performance Improvement	Blood Pressure

Measure ID/ Title	Measure Description	Measure Steward	Topic Area
# 1668 <b>Laboratory Testing (Lipid Profile)</b>	Percentage of patients aged 18 years and older with a diagnosis of CKD (stage 3, 4 or 5, not receiving RRT) who had a fasting lipid profile performed and results documented at least once within a 12-month period	American Medical Association-Physician Consortium for Performance Improvement	CVD (lipid profile)
# 0626 <b>Chronic Kidney Disease – Lipid Profile Monitoring</b>	Percentage of patients with chronic kidney disease that have been screened for dyslipidemia with a lipid profile	Active Health Management	CVD (lipid profile)
# 0627 <b>Chronic Kidney Disease with LDL Greater than or equal to 130 – Use of Lipid Lowering Agent</b>	Percentage of patients with chronic kidney disease and an LDL greater than or equal to 130mg/dl that have a current refill for a lipid lowering agent	Active Health Management	CVD (lipid profile)
# 0250 <b>Hemodialysis Adequacy Clinical Performance Measure III: Hemodialysis Adequacy- HD Adequacy CPM III: Minimum Delivered Hemodialysis Dose</b>	Percentage of all adult ( $\geq 18$ years old) patients in the sample for analysis who have been on hemodialysis for 6 months or more and dialyzing thrice weekly whose average delivered dose of hemodialysis (calculated from the last measurements of the month using the UKM or Daugirdas II formula) was a $spKt/V \geq 1.2$ during the study period.	Centers for Medicare & Medicaid Services	Dialysis adequacy (HD)
# 0247 <b>Hemodialysis Adequacy Clinical Performance Measure I: Hemodialysis Adequacy- Monthly measurement of delivered dose</b>	Percentage of all adult ( $\geq 18$ years old) HD patients in the sample for analyses with documented monthly adequacy measurements ( $spKt/V$ ) or its components in the calendar month	Centers for Medicare & Medicaid Services	Dialysis adequacy (HD)
# 0248 <b>Hemodialysis Adequacy Clinical Performance Measure II: Method of Measurement of Delivered Hemodialysis Dose</b>	Percentage of all adult ( $\geq 18$ years old) in-center HD patients in the sample for analyses for whom delivered HD dose was calculated using UKM or Daugirdas II during the study period and for whom the frequency of HD per week is specified.	Centers for Medicare & Medicaid Services	Dialysis adequacy (HD)

Measure ID/ Title	Measure Description	Measure Steward	Topic Area
<b># 0249</b> <b>Hemodialysis Adequacy Clinical Performance Measure III: Hemodialysis Adequacy--HD Adequacy-- Minimum Delivered Hemodialysis Dose</b>	Percentage of all adult ( $\geq 18$ years old) patients in the sample for analysis who have been on hemodialysis for 6 months or more and dialyzing thrice weekly whose average delivered dose of hemodialysis (calculated from the last measurements of the month using the UKM or Daugirdas II formula) was a $\text{spKt/V} \geq 1.2$ during the study period.	Centers for Medicare & Medicaid Services	Dialysis adequacy (HD)
<b># 0323</b> <b>Hemodialysis Adequacy: Solute</b>	Percentage of calendar months within a 12-month period during which patients aged 18 years and older with a diagnosis of ESRD receiving hemodialysis three times a week have a $\text{spKt/V} > \text{ or } = 1.2$	American Medical Association-Physician Consortium for Performance Improvement	Dialysis adequacy (HD)
<b># 0253</b> <b>Peritoneal Dialysis Adequacy- Measurement of total Solute Clearance at regular intervals</b>	Percentage of all adult ( $\geq 18$ years old) peritoneal dialysis patients with total solute clearance for urea (endogenous residual renal urea clearance & dialytic) measured at least once in a four month time period.	Centers for Medicare & Medicaid Services	Dialysis adequacy (PD)
<b># 0254</b> <b>Peritoneal Dialysis Adequacy- Calculate Weekly KT/Vurea in the Standard Way</b>	Percentage of all adult $\geq 18$ years old) peritoneal dialysis patients who have: <ul style="list-style-type: none"> <li>• Weekly Kt/Vurea used to measure delivered peritoneal dialysis dose and endogenous renal urea clearance</li> <li>• Residual renal function (unless negligible [<math>&lt; 100</math> mL urine in 24 hours]) is assessed by measuring the renal component of Kt/Vurea and estimating the patient's glomerular filtration rate (GFR) by calculating the mean of urea and creatinine clearance</li> <li>• Total body water (V) estimated by either the Watson or Hume method using actual body weight, and BSA estimated by either the Dubois and Dubois method, the Gehan and George method or the Haycock method of using actual body weight, during the four month study period</li> </ul>	Centers for Medicare & Medicaid Services	Dialysis adequacy (PD)
<b># 0318</b> <b>Peritoneal Dialysis Adequacy- Delivered Dose of peritoneal dialysis above minimum</b>	Percentage of all adult ( $\geq 18$ years old) peritoneal dialysis patients whose delivered peritoneal dialysis dose was a weekly Kt/Vurea of at least 1.7 (dialytic + residual) during the four month study period.	Centers for Medicare & Medicaid Services	Dialysis adequacy (PD)

Measure ID/ Title	Measure Description	Measure Steward	Topic Area
# 0321 Peritoneal Dialysis Adequacy: Solute	Percentage of patients aged 18 years and older with a diagnosis of ESRD receiving peritoneal dialysis who have a total Kt/V = 1.7 per week measured within the first month after starting dialysis therapy and at least once every 4 months thereafter	American Medical Association-Physician Consortium for Performance Improvement	Dialysis adequacy (PD)
# 0255 Measurement of Serum Phosphorus Concentration	Percentage of all adult (>= 18 years of age) peritoneal dialysis and hemodialysis patients included in the sample for analysis with serum phosphorus measured at least once within month.	Centers for Medicare & Medicaid Services	Mineral Metabolism
# 0261 Measurement of Serum Calcium Concentration	Percentage of all adult peritoneal dialysis and hemodialysis patients included in the sample for analysis with serum calcium measured at least once within month	Centers for Disease Control and Prevention	Mineral Metabolism
# 0570 CHRONIC KIDNEY DISEASE (CKD): MONITORING PHOSPHORUS	To ensure that members with chronic kidney disease (CKD) who are not on dialysis are monitored for blood phosphorus levels at least once annually.	IMS Health	Mineral Metabolism (CKD)
# 0571 CHRONIC KIDNEY DISEASE: MONITORING PARATHYROID HORMONE (PTH)	To ensure that members with chronic kidney disease, who are not undergoing dialysis, are monitored for PTH levels at least once annually.	IMS Health	Mineral Metabolism (CKD)
# 0574 CHRONIC KIDNEY DISEASE (CKD): MONITORING CALCIUM	To ensure that members with chronic kidney disease (CKD), but who are not on dialysis, are monitored for blood calcium levels at least annually.	IMS Health	Mineral Metabolism (CKD)
# 1655 ESRD patients with PTH >400pg/mL and not treated with a calcimimetic or vitamin D analog.	Percentage of end stage renal disease (ESRD) patients aged 18 years and older with serum intact PTH levels >400pg/mL who are NOT treated with a calcimimetic agent or vitamin D analog to lower the PTH during the 3-month reporting period.	Amgen, Inc.	Mineral Metabolism (ESRD)
# 1658 ESRD patients with PTH <130pg/mL and continued treatment with a calcimimetic or vitamin D analog.	Percentage of end stage renal disease (ESRD) patients aged 18 years and older with serum intact PTH levels <130pg/mL who continue to be treated with a calcimimetic agent or vitamin D analog during the 3-month reporting period.	Amgen, Inc.	Mineral Metabolism (ESRD)

Measure ID/ Title	Measure Description	Measure Steward	Topic Area
<b># 0369</b> <b>Dialysis Facility Risk-adjusted Standardized Mortality Ratio (32) Level</b>	Risk-adjusted standardized mortality ratio for dialysis facility patients.	Centers for Medicare & Medicaid Services	Mortality
<b># 0320</b> <b>Patient Education Awareness—Physician Level</b>	Percentage of end stage renal disease (ESRD) patients aged 18 years and older with medical record documentation of a discussion of renal replacement therapy modalities (including hemodialysis, peritoneal dialysis, home hemodialysis, transplants and identification of potential living donors, and no/cessation of renal replacement therapy) at least once during the 12-month reporting period.	Kidney Care Quality Alliance	Patient Education
<b># 0324</b> <b>Patient Education Awareness—Facility Level</b>	Percentage of a physician’s end stage renal disease (ESRD) patients aged 18 years and older with medical record documentation of a discussion of renal replacement therapy modalities (including hemodialysis, peritoneal dialysis, home hemodialysis, transplants and identification of potential living donors, and no/cessation of renal replacement therapy) at least once during the 12-month reporting period.	Kidney Care Quality Alliance	Patient Education
<b># 0260</b> <b>Assessment of Health-related Quality of Life in Dialysis Patients</b>	Percentage of dialysis patients who receive a health-related quality of life assessment using the KDQOL-36 (36-question survey that assesses patients’ functioning and well-being) at least once per year.	The RAND Corporation	Patient Education
<b># 0259</b> <b>Hemodialysis Vascular Access - Decision-making by Surgeon to Maximize Placement of Autogenous Arterial Venous Fistula</b>	Percentage of patients with advanced chronic disease (CKD4 or 5) or end-stage renal disease (ESRD) undergoing open surgical implantation of permanent hemodialysis access who receive an autogenous arteriovenous fistula (AVF).	Society for Vascular Surgery	Vascular Access
<b># 0256</b> <b>Hemodialysis Vascular Access- Minimizing use of catheters as Chronic Dialysis Access</b>	Percentage of patients on maintenance hemodialysis during the last HD treatment of study period with a chronic catheter continuously for 90 days or longer prior to the last hemodialysis session	Centers for Medicare and Medicaid Services	Vascular Access
<b># 0257</b> <b>Hemodialysis Vascular Access- Maximizing Placement of Arterial Venous Fistula (AVF)</b>	Percentage of patients on maintenance hemodialysis during the last HD treatment of month using an autogenous AV fistula with two needles	Centers for Medicare and Medicaid Services	Vascular Access

Measure ID/ Title	Measure Description	Measure Steward	Topic Area
<b># 0251</b> <b>Vascular Access—Functional AVF or Evaluation by Vascular Surgeon for Placement</b>	<p>Percentage of end stage renal disease (ESRD) patients aged 18 years and older receiving hemodialysis during the 12-month reporting period and on dialysis &gt;90 days who:</p> <p>(1) have an functional (defined as two needles used) autogenous arteriovenous fistula (AVF); or</p> <p>(2) do not have such a fistula but have been seen/evaluated by a vascular surgeon or other surgeon qualified in the area of vascular access for a functional autogenous AVF at least once during the 12-month reporting period.</p>	Kidney Care Quality Alliance	Vascular Access
<b># 0262</b> <b>Vascular Access—Catheter Vascular Access and Evaluation by Vascular Surgeon for Permanent Access.</b>	<p>Percentage of patients aged 18 years and older with a diagnosis of end stage renal disease (ESRD) with a catheter after 90 days on hemodialysis who are seen/evaluated by a vascular surgeon or other surgeon qualified in the area of vascular access for permanent vascular access at least once during the 12-month reporting period.</p>	Kidney Care Quality Alliance	Vascular Access